Loading…
Employees: 2,012
Size RPG Life Sciences (RPGLIFE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $448M, the 888th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹2,554 on 6 Nov 2026.
Performance Over six months the shares gained 2.5%, against -18.1% for the median peer and 0.0% for the India market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 11.8% over the last twelve months (peer median -2.3%); the operating margin is 18.1% (peer median 1.8%).
Valuation It trades at 5.8× enterprise value to sales against a peer median of 4.3× (7th most expensive of 20).
Capital Return on invested capital runs 2.9 points above its cost of capital (13.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹7.34B | ₹7.04B | ₹6.50B | ₹5.79B | ₹5.10B |
| Revenue growth | — | +8% | +12% | +13% | — |
| Gross profit | ₹3.06B | ₹2.44B | ₹2.45B | ₹2.07B | ₹1.70B |
| EBITDA | ₹1.55B | ₹1.47B | ₹1.60B | ₹1.27B | ₹1.03B |
| Net income | ₹1.20B | ₹1.15B | ₹1.83B | ₹877M | ₹676M |
| Free cash flow | n/a | -₹800,000 | ₹444M | ₹261M | ₹606M |
| Capital expenditure | n/a | ₹654M | ₹360M | ₹692M | ₹327M |
| Total debt | n/a | ₹200M | ₹0 | ₹0 | ₹100,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RPGLIFE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.7% | -14.7% | 9th highest of 20 |
| 6-month return | +2.5% | -18.1% | 5th highest of 19 |
| Distance from 52-week high | -18.4% | -41.5% | 4th highest of 20 |
| Revenue growth (TTM) | +11.8% | -2.3% | 7th highest of 20 |
| Operating margin | 18.1% | 1.8% | 2nd highest of 20 |
| EV / Sales | 5.8× | 4.3× | 7th most expensive of 20 |
| ROIC minus cost of capital | +2.9 pp | -4.8 pp | 4th highest of 19 |
| EV / EBITDA | 27.3× | 20.7× | 2nd most expensive of 5 |
| Net debt / EBITDA | -1.6× | 2.0× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | 5.8× | n/a | n/a |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 1.8× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | 4.3× | 23.7% | +28.2% |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | 6.0× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | 2.5× | 6.5% | +15.3% |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | 10.5× | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | 4.4× | n/a | n/a |
| Beijing Foyou Pharma 601089.SS | China | $455M | -24% | +5% | 10% | 0.2× | n/a | n/a |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $463M | -21% | +7% | 19% | 3.6× | 7.1% | +1.3% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $464M | -30% | +14% | 5% | 2.4× | 2.5% | -1.3% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | 5.7× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $464M | -22% | -2% | -2% | 10.4× | 33.5% | -0.9% |
| Teyi Pharmaceutical 002728.SZ | China | $465M | -9% | -7% | 7% | 3.5× | 26.6% | +8.0% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 1.6× | 19.7% | +3.5% |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 2.0× | 9.9% | +6.7% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $428M | -51% | -24% | -6% | 7.0× | n/a | n/a |
| Phathom Pharmaceuticals PHAT | United States | $427M | -57% | +87% | -9% | 2.9× | n/a | n/a |